Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease


Avataneo, Valeria, de Nicolò, Amedeo, Cusato, Jessica, Antonucci, Miriam, Manca, Alessandra, Palermiti, Alice, Waitt, Catriona ORCID: 0000-0003-0134-5855, Walimbwa, Stephen, Lamorde, Mohammed, di Perri, Giovanni et al (show 1 more authors) (2020) Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease Journal of Antimicrobial Chemotherapy, 75 (7). pp. 1772-1777. ISSN 0305-7453, 1460-2091

[thumbnail of Manuscript RDV_author accepted version.docx] Text
Manuscript RDV_author accepted version.docx - Author Accepted Manuscript
Download (281kB)

Abstract

Abstract Background Remdesivir has received significant attention for its potential application in the treatment of COVID-19, caused by SARS-CoV-2. Remdesivir has already been tested for Ebola virus disease treatment and found to have activity against SARS and MERS coronaviruses. The remdesivir core contains GS-441524, which interferes with RNA-dependent RNA polymerases alone. In non-human primates, following IV administration, remdesivir is rapidly distributed into PBMCs and converted within 2 h to the active nucleoside triphosphate form, while GS-441524 is detectable in plasma for up to 24 h. Nevertheless, remdesivir pharmacokinetics and pharmacodynamics in humans are still unexplored, highlighting the need for a precise analytical method for remdesivir and GS-441524 quantification. Objectives The validation of a reliable UHPLC-MS/MS method for remdesivir and GS-441524 quantification in human plasma. Methods Remdesivir and GS-441524 standards and quality controls were prepared in plasma from healthy donors. Sample preparation consisted of protein precipitation, followed by dilution and injection into the QSight 220 UHPLC-MS/MS system. Chromatographic separation was obtained through an Acquity HSS T3 1.8 μm, 2.1 × 50 mm column, with a gradient of water and acetonitrile with 0.05% formic acid. The method was validated using EMA and FDA guidelines. Results Analyte stability has been evaluated and described in detail. The method successfully fulfilled the validation process and it was demonstrated that, when possible, sample thermal inactivation could be a good choice in order to improve biosafety. Conclusions This method represents a useful tool for studying remdesivir and GS-441524 clinical pharmacokinetics, particularly during the current COVID-19 outbreak.

Item Type: Article
Uncontrolled Keywords: Humans, Pneumonia, Viral, Hemorrhagic Fever, Ebola, Coronavirus Infections, Alanine, Adenosine Monophosphate, Adenosine Triphosphate, Chromatography, High Pressure Liquid, Sensitivity and Specificity, Tandem Mass Spectrometry, Pandemics, Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment
Depositing User: Symplectic Admin
Date Deposited: 18 May 2020 09:50
Last Modified: 01 Mar 2026 00:52
DOI: 10.1093/jac/dkaa152
Related Websites:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3086550
Disclaimer: The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.
Altmetric
CORE (COnnecting REpositories)